Lilly cancer R&D chief Bilenker quits, handing reins to deputy Concert dumps schizophrenia drug CTP-692 after failing phase 2 Gilead Sciences pens early-stage HIV vaccine pact with Gritstone Oncology In Partnership: Meeting the commercialization challenge of a surging gene and cell therapy market Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs Takeda GI veteran Parikh takes charge at 'molecular machines' biotech MOMA Therapeutics Vanderbilt scientists outsmart an 'undruggable' cancer-driving gene with engineered mutations FDA approves Medtronic's diamond-laden heart ablation catheter Featured Story | By Amirah Al Idrus Eli Lilly’s cancer R&D chief Josh Bilenker, M.D., is hitting the exit. His departure comes two years after the Big Pharma ponied up $8 billion for Bilenker’s startup, Loxo Oncology, and one year after it combined the oncology team at Lilly Research Laboratories with the Loxo team—and put Bilenker and two other Loxo executives in charge. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor A phase 2 clinical trial of Concert Pharmaceuticals’ CTP-692 in schizophrenia patients has missed its primary endpoint. The setback led Concert to stop development of the deuterated form of D-serine and focus on a phase 3 treatment for a form of hair loss. read more By Ben Adams Initially known as a machine learning biotech focused on cancer, Gritstone Oncology has been broadening its scope to include a very early look at treatments for COVID-19 and, now, another infectious disease. read more In Partnership With: AmerisourceBergen Undaunted by the challenges the COVID-19 pandemic unleashed on the world the expected surge of cell and gene therapies already in the pipeline and on the horizon will continue to materialize, and with them the complexity of riding that wave of innovation. read more By Nick Paul Taylor Horizon Therapeutics has struck a $3 billion deal to buy AstraZeneca spinout Viela Bio. The takeover will give Horizon a clutch of clinical-phase autoimmune and inflammatory disease drug candidates, R&D capabilities and an approved monoclonal antibody. read more By Ben Adams After breaking cover last April to go after a whole new class of medicine, Third Rock Ventures' MOMA Therapeutics has grabbed a new chief to take the helm. read more By Arlene Weintraub Scientists at Vanderbilt University have developed a novel way to disrupt the oncogene MYC by genetically modifying it so it cannot interact with the protein HCF1. The method, developed in Burkitt lymphoma cells, caused tumors to rapidly shrink in mouse models. read more By Conor Hale The FDA approved Medtronic’s DiamondTemp irrigated ablation catheter, designed to treat patients with recurrent atrial fibrillation that has not responded to drug therapies. read more | | LabConnect is the preeminent provider of central laboratory support services for logistically and analytically complex studies - customizable to meet the unique needs of your clinical trials. We are your connection to confidence. Contact us today. |
Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Fierce JPM Week January 11–13, 2021, 10AM ET | Virtual Event Virtual Clinical Trials Summit February 9-10, 2021 | Virtual Event Learn what it takes to get a drug developed and approved February 23-24, 2021 | 9:00a.m.-3:30p.m. PST For non-scientists. Learn the science driving biopharma. February 25-26, 2021 | 9:00a.m.-3:30p.m. EST Learn what it takes to get a drug developed and approved March 9-10, 2021 | 9:00a.m-3:30p.m EST Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 9:00a.m-3:30p.m PST Learn what it takes to get a drug developed and approved April 13-14, 2021 | 9:00 a.m. - 3:30 p.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 9:00 a.m. -3:30 p.m. PST Learn what it takes to get a drug developed and approved April 22-23, 2021 | 9:00 a.m. - 3:30 p.m. EST Learn the science driving biopharma. Specific for the non-scientist. May 6-7, 2021 | 9:00 a.m. - 3:30 p.m. EST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 9:00 a.m. -3:30 p.m. PST Learn what it takes to get a drug developed and approved June 2-3, 2021 | 9:00 a.m. -3:30 p.m. EST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9:00 a.m. -3:30 p.m. EST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. | 